A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Phase 1
200
about 2.5 years
18+
6 sites in CO, FL, MA +2
About this study
This trial is testing the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. It includes three parts: a dose escalation trial of STRO-004 monotherapy, a cohort expansion to further evaluate STRO-004 monotherapy, and a dose escalation of STRO-004 combined with pembrolizumab.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Pembrolizumab
- 2.Take STRO-004
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Part 1A, 1B: Percentage of participants with Treatment-Emergent Adverse Events (TEAEs), with severity determined according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grading scale, Part 1B: Disease control rate (DCR), Part 1B: Duration of Response (DOR), Part 1B: Objective Response Rate (ORR), Part 1B: Progression-Free Survival (PFS), Part 1C: Percentage of participants with TEAEs, with severity determined according to the CTCAE v5.0 grading scale
Secondary: Part 1A, 1C: Disease Control Rate (DCR), Part 1A, 1C: Duration of Response (DOR), Part 1A,1C: Progression-Free Survival (PFS), Part 1A: Objective Response Rate (ORR)
Oncology